On October 22, 2026, trial NCT05834777 involving icatibant was listed as active but not recruiting. The study, titled "Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor," is a Phase 3 trial. Icatibant is an approved compound being evaluated in this trial for its effect on bradykinin B2 receptor inhibition in the context of intradialytic hypotension prevention.
The trial's current status indicates that enrollment is closed but the study has not yet concluded. No results have been posted for this trial as of the listed date. The trial record does not provide additional detail on outcomes, participant numbers, or findings at this stage.
This update reflects only the trial's status change as recorded on ClinicalTrials.gov. No efficacy or safety conclusions can be drawn from a status update alone. Further updates may follow as the trial progresses toward completion and eventual reporting of results.
Readers interested in icatibant's broader background and regulatory history can consult the compound overview for additional context.